What's New in DED in 2026? - Summary - MDSpire

What's New in DED in 2026?

"It's all about finding what's wrong with <em>your</em> patient

  • January 1, 2026

  • 1 min

Share

Objective:

To discuss advancements in the management of dry eye disease (DED) as presented at SECO 2026.

Key Findings:
  • New medications targeting specific root causes of dry eye disease are expected to be available in 2026.
  • The TFOS DEWS III framework provides a structured approach to diagnosing and treating DED.
Interpretation:

The advancements in medication and the structured approach from TFOS DEWS III are expected to enhance the management of dry eye disease.

Limitations:
Conclusion:

The developments in 2026 signify a promising direction for more effective treatment of dry eye disease.

Original Source(s)

What's New in DED in 2026?

  • January 1, 2026

Related Content

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

  • January 14, 2026

  • 3 min
Elevating Ocular Surface Care

The trilayer decellularized basement membrane is used in ocular surgery and in OSD applications, including corneal and conjunctival-related injuries or defects.

Red Eye, Global Challenge

Narrative review calls for clearer guidance on noninfectious conjunctival hyperemia

  • March 18, 2026

  • 2 min